Loading...
XASXALA
Market cap115mUSD
Dec 27, Last price  
0.18AUD
1D
0.00%
1Q
9.38%
Name

Arovella Therapeutics Ltd

Chart & Performance

D1W1MN
XASX:ALA chart
P/E
—
P/S
10,905.49
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
51.91%
Rev. gr., 5y
-57.45%
Revenues
17k
-95.81%
8,172,8278,338,5329,508,16111,856,26019,35314,2153,003,7983,908,8694,045,0608,648,1875,624,8155,785,8027,221,385425,8641,219,083532,690257,347295,810405,89817,000
Net income
-9m
L-14.10%
-1,928,929-265,990-1,773,200-9,199,611-3,002,752-4,856,312-4,508,938-4,595,023-1,667,519-2,051,794-3,367,191-2,230,877-1,238,309-5,459,278-7,795,039-9,943,909-5,047,465-8,620,588-10,181,351-8,746,035
CFO
-7m
L+8.07%
00000000-1,609,288-2,614,630-3,154,407-1,802,103-854,223-2,548,030-2,495,488-2,883,725-3,544,528-6,268,245-6,397,650-6,913,872
Earnings
Feb 26, 2025

Profile

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
URL
https://www.arovella.com/
IPO date
Jan 24, 2002
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
17
-95.81%
406
37.22%
296
14.95%
Cost of revenue
10,828
10,927
5,596
Unusual Expense (Income)
NOPBT
(10,811)
(10,521)
(5,301)
NOPBT Margin
Operating Taxes
(1,049)
195
Tax Rate
NOPAT
(10,811)
(9,472)
(5,495)
Net income
(8,746)
-14.10%
(10,181)
18.11%
(8,621)
70.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
14,609
5,478
6,256
BB yield
-11.08%
-15.40%
Debt
Debt current
67
Long-term debt
221
Deferred revenue
Other long-term liabilities
16
9
Net debt
(12,714)
(5,175)
(5,782)
Cash flow
Cash from operating activities
(6,914)
(6,398)
(6,268)
CAPEX
(129)
(3)
(566)
Cash from investing activities
(179)
95
(566)
Cash from financing activities
14,609
5,407
6,188
FCF
(10,893)
(9,151)
(5,434)
Balance
Cash
12,714
5,175
6,071
Long term investments
Excess cash
12,714
5,155
6,056
Stockholders' equity
11,228
3,780
7,617
Invested Capital
16
9
1,715
ROIC
ROCE
EV
Common stock shares outstanding
941,423
711,483
549,624
Price
0.14
180.00%
0.05
 
Market cap
131,799
270.49%
35,574
 
EV
119,085
30,399
EBITDA
(10,768)
(9,684)
(4,749)
EV/EBITDA
Interest
9
21
195
Interest/NOPBT